Passion - Teamwork - Expertise

  • Our Passion: "Helping people suffering from lung disease."

  • Our Teamwork: "Nobody does it all by themselves. Everybody counts."

  • Our Expertise: "We've spent our careers in lung disease. The work is still not done."

 

Pulmonary diseases are on the rise, and mean a substantial burden on patients, caregivers, and society.

 

At Qrumpharma (pronounced 'quorum pharma') we are passionate about treating lung diseases, we know that it takes a team to find the answer. We scour the world for the best drugs and combine them with the best available aerosol drug delivery technology to create innovative products that will improve people's lives.

 

Our team of experienced drug development professionals has a long history of successful drug development of pulmonary products and has the technical, clinical, and regulatory expertise to reduce development risk and minimize development timelines.

About Us

 

Qrumpharma is a Pennsylvania-based pharmaceutical company focused on developing first-in-class therapeutics for the treatment of severe chronic and recurrent pulmonary infections and diseases, such as those caused by Nontuberculous Mycobacteria (NTM) and Tuberculosis.

 

The name Qrumpharma is derived from quorum sensing, in which colonies of bacteria can work together to be more successful than an individual. Quorum sensing exemplifies the sense of teamwork at Qrumpharma. The Qrumpharma team consists of experienced entrepreneurs working together to develop novel products and bring them to the market place. Our focus is to do the proper science at the proper time to minimize development times and development risks.

NTM and Tuberculosis

 

NTM

Nontuberculous mycobacteria (NTM) are pervasive throughout the world, and readily found in soil and water.  In some people, NTM can colonize the airways and lead to serious lung infections. In the US, over 80,000 people suffer from NTM lung infections, worldwide, more than 500,000, and the number is increasing rapidly1.

 

Tuberculosis

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis which generally affects the lungs. Tuberculosis, historically known as "consumption", has been present in humans since ancient times. One fourth of the world's population, is infected with TB and in 2017 there were more than 10 million new cases of active TB resulting in 1.3 million deaths2. The World Health Organization declared TB a "global health emergency" in 19943.

 

1: https://www.lung.org/lung-health-and-diseases/lung-disease-lookup/nontuberculosis-mycobacteria/learn-about-ntm.html

2: https://www.cdc.gov/tb/statistics/default.htm

3: https://apps.who.int/iris/handle/10665/58749

 

 

Pipeline

 

QRM-003

QRM-003 is a novel formulation of the known antibiotic clofazimine that is inhaled directly to the lungs via a nebulizer. Clofazimine has shown efficacy against a wide range of NTM isolates including M. avium and M. abscessus. If taken orally, clofazimine tends to accumulate in the liver and spleen first, before the lungs, making clofazimine a prime candidate for inhaled delivery. Qrumpharma is currently conducting acute toxicology studies to enable first in human dosing.

 

QRM-007

QRM-007 is an inhaled formulation of clofazimine for the treatment of TB. QRM-007 is similar to QRM-003, except that the product is optimized for the low resource settings where TB is more common. QRM-007 will closely follow QRM-003 development to leverage early stage non-clinical and clinical results.

 

QRM-008

QRM-008 is a novel inhaled formulation of an existing antibiotic that has demonstrated efficacy against both NTM and TB. Prototype formulations have been developed, and in vivo studies in models of NTM and TB pulmonary disease are in preparation. Furthermore, QRM-008 shows synergistic activity with clofazimine, opening the potential for combination products in the future.

 

 

Technology

 

Update

Content will be updated soon.

News and Press Releases


October 31 - November 02, 2019

Qrumpharma Poster presentation at NACFC 2019, nashville, TN

                                                  

Qrumpharma's Drs. Brandon Banaschewski and Thomas Hofmann present poster entitled "Tissue Distribution of Inhaled Clofazimine in Both Naïve and Infected Mouse Models" at the 33rd. Annual North American Cystic Fibrosis Conference (NACFC).

                                     


August 21, 2019

Qrumpharma Announces EMA Orphan Drug Designation for QRM-003 for the Treatment of pulmonary NTM infections

                                                  

Qrumpharma Inc., a privately held pre-clinical drug development company developing therapeutics for prevention and treatment of infectious diseases, announced today that the European Medicines Agency  (EMA) has granted Orphan Drug Designation (ODD) to QRM-003 for the treatment of pulmonary infections with non-tuberculous mycobacteria (NTM). QRM-003 is a formulation based on a re-purposed antibiotic for inhalation administration.

 

The EMA through its Committee for Orphan Medical Products (COMP) provides incentives for sponsors/pharmaceutical industry to develop drugs for rare diseases with a prevalence of  less than 5/100,000 in the European Union. These incentives may include EU market exclusivity (10 years following approval), EMA protocol assistance to meet European regulatory requirements, fee reductions, and grants from EU programmes and initiatives supporting research and development.

 

NTM infections can occur throughout the body, although pulmonary infections, lymphadenitis, and skin and soft tissue infections are the most common; NTM infections have been increasing worldwide over the past two decades; Treatment is typically prolonged and requires multi-drug regimens due to the risk of development of resistance.

 


July 31, 2019

 

Qrumpharma Sponsors Doylestown Elite Cycling Team

 

Qrumpharma recognized as sponsor of Doylestown Cycling Team "Bike Works". Details can be found here:

 

https://www.doylestownbikeworks.com/team/news/get-to-qrumpharma

 

 

 

July 19, 2019

 

Qrumpharma Review Article "inhaled antibiotics for mycobacterial Lung disease" in the Journal of Pharmaceutics

 

Today, the MDPI Pharmaceutics Journal published a review article on an important area of drug development - the inhaled application of antiinfectives for patients with NTM (nontuberculous mycobacteria) lung disease. Dr. Brandon Banaschewski did a nice job describing the current activities and promise for patients with this serious lung infection. We all hope those approaches will soon yield novel treatments for patients. Here is the link for the open source article:

 

Abstract: https://www.mdpi.com/1999-4923/11/7/352

PDF Version: https://www.mdpi.com/1999-4923/11/7/352/pdf

 

Thomas Hofmann MD PhD

CEO, Qrumpharma

 

 

July 12, 2019

 

Qrumpharma presents at the 5th. Annual "entrepreneur spotlight"

 

Qrumpharma's Dr. Brandon Banschewski presented today at the 5th. Annual "Entrepreneur Spotlight" at the Pennsylvania Biotechnology Center (PABC) in Doylestown. The Spotlight is a Shark Tank-style event showcasing companies based at the center to potential investors. Nearly 100 area business leaders and biotech investors were in attendance.

 

 

 


May 26, 2019

 

Qrumpharma Article in the Journal of Cystic Fibrosis

 

After some years of hard work on formulation, doing animal experiments, and learning about nontuberculous mycobacteria, it is exciting to see yesterday's publication in the Journal of Cystic Fibrosis. Here is the link:

 

https://www.cysticfibrosisjournal.com/article/S1569-1993(19)30765-9/fulltext

 

In particular, we should point out the creative and collaborative work of the team, and the support of those that believe the inhaled route for treating difficult lung disease holds a lot of promise. We are grateful to everybody who supported the idea and execution of the program, and appreciate their continued support.

 

Thomas Hofmann MD PhD

CEO, Qrumpharma

 

 

April 12, 2019

 

Qrumpharma Spring Meeting 2019 in Germany

 

See the coverage of our Spring Meeting 2019 in the German local newspaper.

English version.

 

Thomas Hofmann MD PhD

CEO, Qrumpharma

 

 

October 18-20, 2018

 

Qrumpharma Poster presentation at NACFC 2018, Denver, CO

 

Qrumpharma Inc. presents poster entitled "Development of QRM-003, a Novel Nebulized Antibiotic for the Treatment of Nontuberculous Mycobacterial Infections in Cystic Fibrosis" at the 32nd annual North American Cystic Fibrosis Conference (NACFC).

 

 

August 17, 2018

 

Qrumpharma Announces FDA Orphan Drug Designation for QRM-003 for the Treatment of pulmonary NTM infections

 

Qrumpharma Inc., a privately held pre-clinical drug development company developing therapeutics for prevention and treatment of infectious diseases, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to QRM-003 for the treatment of pulmonary infections with non-tuberculous mycobacteria (NTM). QRM-003 is a formulation based on a re-purposed antibiotic for inhalation administration.

 

The US FDA Orphan Drug Designation provides incentives for companies to develop drugs for rare diseases affecting fewer than 200,000 patients in the US. These incentives may include FDA assistance in clinical trial design, tax credits towards the cost of clinical trials, prescription drug user fee waivers, and potential market exclusivity for seven years following approval.

 

NTM infections can occur throughout the body, although pulmonary infections, lymphadenitis, and skin and soft tissue infections are the most common; NTM infections have been increasing worldwide over the past two decades; Treatment is typically prolonged and requires multi-drug regimens due to the risk of development of resistance.

 

 

August 15, 2018

 

Qrumpharma starts SBIR contract with NIH/NIAID

 

Qrumpharma started today the award period for the phase 1 SBIR contract HHSN272201800041C with the National Institute of Allergy and Infectious Diseases. This contract is entitled "Development of a Clofazimine Aerosol Formulation for the Treatment of Tuberculosis" with a budget period of 18 months. Qrumpharma's CEO Dr. Thomas Hofmann is serving as Principal Investigator.

 

 

July 11, 2018

 

FDA Grants Qualified Infectious Disease Product (QIDP) Designation to QRM-003, Qrumpharma’s Anti-infective Product Candidate

 

Qrumpharma Inc., a privately held pre-clinical drug development company developing therapeutics for prevention and treatment of infectious diseases, announced today that the US Food and Drug Administration (FDA) has granted a qualified infectious disease product (QIDP) designation to Qrumpharma’s investigational antiinfective product candidate, QRM-003. The QIDP designation is for the treatment of pulmonary infections with non-tuberculous mycobacteria (NTM).

 

The QIDP designation was created by the Generating Antibiotic Incentives Now (GAIN) Act, which was part of the FDA Safety and Innovation Act of 2012 (FDASIA). It provides certain incentives for the development of new anti-infectives, including eligibility for priority review, the FDA’s Fast Track program, and a five-year extension of exclusivity under the Hatch-Waxman Act.

 

NTM infections can occur throughout the body, although pulmonary infections, lymphadenitis, and skin and soft tissue infections are the most common; NTM infections have been increasing worldwide over the past two decades; Treatment is typically prolonged and requires multi-drug regimens due to the risk of development of resistance.

 

 

May 18-23, 2018

 

Qrumpharma Talk at ATS conference 2018, San Diego, CA

 

Qrumpharma's CEO Dr. Thomas Hofmann gives an oral presentation entitled "Development and Efficacy of Novel Antibiotic Formulations for the Treatment of Mycobacterium abscessus Pulmonary Infections" at the American Thoracic Society's Annual Meeting in San Diego, CA.

 


November 2-4, 2017

 

Qrumpharma Poster presentation at NACFC 2017, indianapolis, IN

 

Qrumpharma Inc. presents poster entitled "The Development of Nebulized Antimycobacterial Antibiotics (QRM-003 and QRM-006) for the Treatment of Nontuberculous Mycobacterial Infections in Cystic Fibrosis Patients" at the 31st annual North American Cystic Fibrosis Conference (NACFC).

 

 

October 10, 2017

 

Talk

 

See our latest presentation at the 4th. International TB-Meeting in Durham, NC, October 16-17, 2017.

 

Thomas Hofmann MD PhD

CEO, Qrumpharma

 

 

July 18, 2017

 

Funding and Progress update

 

To our friends, colleagues, and supporters

 

Qrumpharma has seen some great progress lately, and I thought it important to update the team and friends on what has happened over the last couple of months:

 

First, we have identified and understood our final two drug candidates for nontuberculous mycobacteria, which are QRM-003 (known drug reformulated) and QRM-006 (novel drug reformulated for inhalation). As part of that finalization, we have finalized a term sheet and material transfer agreement on the novel drug, with our Chinese partner.

 

Second (and perhaps most importantly), we have executed the contract with the CF Foundation, for a grant (non dilutive, and as a direct, non conditional payment) to develop our two drug candidates for NTM. We are now funded for the microbiological and animal proof of concept (by CFF), and for the formulation development of the drug candidates into an aerosol formulation. The points above are major accomplishments, and I want to thank Stefan Ufer and Brandon Banaschewski for their great and passionate work to get us the CFF grant. The funding from the CF Foundation validates our scientific approach and the great unmet need in NTM, and puts our work on the map. In addition, I have received an invitation to speak at the TB conference at Duke University in Durham, NC.

 

The next steps will be to rapidly execute on formulation, and on the above NTM testing (at Colorado State, and at Rutgers University), and use those results to further strengthen our Intellectual Property.

 

And last, we have brought in a substantial investment round, to fund operations (along with aerosol formulation, preclinical work and toxicology) for 1.5 to 2 years. Along with that come two phenomenal board members/advisors, each of them extremely valuable to Qrum strategy and development.

 

Our current focus is to increase our IP portfolio by producing formulation and animal data, execute the CFF funded experiments, and move fast towards the preclinical and toxicology experiments.

 

Please let me know if there are any questions about the development and company progress, or want to know more detail. We are excited and energized to make a difference in severe lung disease.

 

Thomas Hofmann MD PhD

CEO, Qrumpharma

 

thofmann@qrumpharma.com

Contact us

Contact Form

Contact Details

For further information or inquiries don't hesitate to contact us.

Dr. Thomas Hofmann, MD PhD

Top